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Crowding of severely ill patients in intensive care units has led worldwide to important increases in nosocomial (ICU- 
related) infections. Moreover, the nature of these hospital-acquired infections is shifting towards Gram-positive micro- 
organisms, yeast and Gram-negative rods, possessing important resistance genes (e.g. extended spectrum beta- 
lactamases and inducible Enterobacteriaceae). Ceftazidime and aztreonam are loosing their activity against the Gram- 
negative microorganisms. The fourth generation cephalosporins have an intrinsic high activity against the inducible 
Enterobacteriaceae. On our Hematology and Intensive Care units, the introduction of cefepime for nosocomial infections 
led to a remarkable drop in the number of Enterobacter isolates combined with important decreases in Enterobacter 
resistance towards several antibiotics. 
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INTRODUCTION 
The already busy intensive care physician is faced with 
an ever increasing problem of bacterial infection- 
colonization in the patients hospitalized on intensive 
care units (ICUs). Prescribing antibiotics is therefore an 
important task. O f  course, other non-antibiotic measures 
are also needed to prevent or treat these infections [l], 
such as isolation procedures, hygienic measures, im- 
proving the general condition of the patient and, if at 
all possible, improving inimunity. Many hospitals are 
currently seeing an increase in the absolute number of 
nosocomial infections, many of them now multiply 
resistant especially on intensive care units [2,3], causing 
increased mortality, length of stay in the ICU or 
hospital and antibiotic use [4,5]. 
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THE IMPORTANCE OF NOSOCOMIAL INFECTIONS 
ON THE INTENSIVE CARE UNIT 
Concentrating sick people in crowded spaces leads to 
an increase in the incidence of infections. This was 
described in the Middle Ages in the pest houses, by 
Semmelweis stressing the importance of hand washing, 
by Florence Nightingale and her ideas about planning 
of hospital facilities [6], and, more recently, by the 
NNIS study [7,8], the SENIC study [9] and the 
ICARE project [2]. 
Modern science has pinpointed the cause of this 
phenomenon to horizontal transfer of microorganisms 
between patients, more vulnerable to infection follow- 
ing different invasive procedures and by general decreases 
in host resistance, due to the steadily increasing age of 
the population, steroids, chemotherapy for cancer, and 
immunosuppressive agents. 
Starting in the 1960s and 1970s the most seriously 
ill patients were gathered in what we now call intensive 
care units (ICUs): units where dedicated, highly trained 
health care workers use complicated machines, invasive 
procedures and multi-drug cocktails in order to sustain 
life in victims, for example, of severe trauma, over- 
whelming infections or cardiovascular crises. The shift 
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of surgical care to outpatient centers leaves the sickest 
patients in hospital, which are becoming more like 
large ICUs and is also leading to a greater prevalence 
of catheter-related blood stream infections and venti- 
lator-associated pneumonias. Naturally, this crowding 
of severely ill patients has led to important increases in 
nosocomial ICU-related infections [10,11]. This was 
nicely demonstrated by the EPIC study: on 29th April 
1992 a one-day prevalence study was carried out in 
17 European countries, including more than 10.000 
patients in 1,472 ICUs [12]. Of all these patients on 
modern ICUs, 45% had some form of infection. Thirty 
per cent were community-acquired, 20% hospital (not 
1CU)-acquired and a startling 50% originated on the 
ICU itself! Of these ICU-acquired infections, two 
thirds were some form of respiratory infection (mainly 
colonization?). Staphylococcus aureus and Pseudomonas 
aeruginosa each were responsible for one third of all 
infections. Another important factor involved in the 
rising numbers of nosocomial infections is the health 
crisis in modern care systems. Several studies suggest a 
link between decreased nurse staffing levels and an 
increased risk of infections [13]. 
The increasing importance of severe infections in 
patients hospitalized on the ICU, combined with the 
ever-present threat of nosocomial infection, makes it 
imperative that the ICU physician has a working 
knowledge of microbiology, epidemiology, hospital 
hygiene, clinical infectious diseases and antibiotic 
therapy. In optimal conditions, he is in daily contact 
with the microbiological laboratory and with the 
consultant in infectious diseases. While each patient 
needs a specific prescription for the treatment of his 
infection, it is also necessary that a more general set of 
rules exist for the geographic area (the unit), in which 
the patient is hospitalized: it has been shown that each 
geographic area harbors its own indigenous microbial 
flora, often with important resistance factors. Unfor- 
tunately, it has been shown that implementation of 
standard accepted practices for prevention of hospital- 
acquired infections is far from satisfactory in European 
hospitals, even in ICUs [14]. 
In order to formulate an optimal antibiotic pre- 
scription, the physician needs hard data. Sometimes this 
is available and a choice can be made based on an 
antibiotic resistance profile. Local prescription guide- 
lines, determined by the hospital antibiotic committee, 
can help in this decision. Much of the time, certainly 
on ICU, an antibiotic has to be chosen on empirical 
grounds: hard data are lacking, or can only be obtained 
after 12-36 hours. This empirical choice is based on 
‘soft’ data. Current microbiological ‘good clinical 
practice’ is available through several textbooks [I 5-17]. 
The hospital antibiotic committee guidelines also offer 
help. In any case, these soft data lead to a ‘best informed 
guess’. A combination of data, such as the suspected 
origin of the infection (e.g. urinary-versus catheter- 
related), the most likely organisms involved, the local 
resistance profile of these microorganisms, and some 
pharmacokinetic influences (e.g. presence of renal 
impairment), lead to a logical choice of one or several 
antibiotics that can be effective in the present clinical 
condition. Whether a single antibiotic only should be 
prescribed, or a combination of agents, is still a topic 
often open to discussion. 
As the endogenous flora and its potential presence 
of resistance genes varies between countries, between 
hospitals and even within the same hospital between 
specific units, it is necessary to formulate a specific set 
of prescription rules for each specific unit. In order to 
do this, the microbiology department must present 
on a regular basis, an overview of all microorganisms 
isolated with their sensitivity patterns. The evolutionary 
changes in the etiology of infections and changes in 
sensitivity, must be followed and be communicated to 
the prescribing physicians. This can best be imple- 
mented by a coritinuing dialogue between the micro- 
biologist, the antibiotics committee and the end user. 
INCREASING ANTIBIOTIC RESISTANCE 
Such continuing evaluation of the organisms present 
on ICUs has led to some important conclusions [18]. 
Increasingly, Gram-positive microorganisms are replac- 
ing the Gram-negative rods in invasive infection on the 
ICU; important differences exist between hospitals 
in the prevalence of oxacillin resistance. Fungi now 
occupy fifth place in the rank order of microorganisms 
isolated from blood cultures; they are also isolated in 
increasing numbers from respiratory samples. Especially 
on ICU, inducible Enterobacteriaceae (Enterobacter, Citro- 
bacter, Morganella, and Serratia spp.) present a special 
problem with increasing resistance towards cephalo- 
sporins and quinolones [ 19-2 11. Within the inducible 
Gram-negatives, Enterobacter spp. species are the most 
common, causing mainly respiratory colonization and/ 
or infection. Less frequently they cause blood stream 
infection or urosepsis. While Pfaller et al. [22] observed 
clonal spread of a single strain within a given in- 
stitution, most of the episodes of bacteremia were 
caused by patient-unique strains of E. cloacae, suggesting 
that selection of mutant subpopulations within each 
patient (endogenous infection) by exposure to beta- 
lactam agents was an important factor in the develop- 
ment of these resistant strains. In order to combat the 
rise in antibiotic resistance, different authors have 
reported on the notion of antibiotic rotation [23]. 
While the idea is now more than ten years old 1241, no 
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convincing studies have been published. Other authors 
stress the fact that, within several antibiotic classes, only 
individual molecules seem to influence a selective 
pressure towards resistance [25]. Take ceftazidime, for 
instance, its use inexorably leads to the selection of 
resistance in inducible Enterobacteriaceae. O n  the other 
hand, this is not a problem with ceftriaxone. Important 
also is the fact that quinolone use selects resistance to 
carbapenems (26,271. 
During their hospitalization period, the exposure 
of patients to parenteral antibiotics rose from 23% in 
1978 to 44% in 1992, with the average number of 
different agents used per patient remaining at 1.8-2.1 
[28]. Of all the available antibiotics, beta-lactam agents 
are the most frequently prescribed, especially the 
cephalosporins (28). In the last decade, ceftazidinie has 
been the mainstay drug on  many haematology units 
and ICUs. However, its use is waning for several 
reasons. Haematology patients present with an increasing 
number of gram-positive infections, for which cefta- 
zidime is not suited (20% resistance in streptococci, 
isolated from blood cultures in haematology and 
oncology patients; MI& 8-32 mg/L in S. aureus). 
Gram-negative infections have shifted from P aeruginosa 
and E. coli towards inducible gram-negative infections, 
for which ceftazidime is losing its activity [19]. 
Furthermore, extended spectrum beta-lactamases lead- 
ing to cefiazidinie resistance have appeared, especially 
in Klebsiella sp. [21]. 
As in other developed countries, strains isolated 
from Belgian patients with nosocomial infections, have 
become more resistant to important antibiotics. An 
ongoing surveillance study on intensive care (the NPRS 
study) shows a trend towards progressive increase in 
resistance of Gram-negative rods; these studies were 
performed in 1991 [29], 1994-1995 [30] and in 1998 
[31] (Figure 1). The problem is especially important for 
piperacillin, imipeneni, ciprofloxacin and ceftazidime. 
Aminoglycosides remain active, with only 2 to 5% 
resistance. Unfortunately, the NPRS study only depicts 
a trend; absolute changes cannot be calculated due to 
important changes in methodology between the 
repetitive studies. 
FOURTH GENERATION CEPHALOSPORINS TO THE 
RESCUE? 
The fourth generation cephalosporins, cefepime and 
cefpirome, became available for clinical use at the 
beginning of the 1990s. Their activity against Gram- 
positive Gicro-organisms is of the same order as 
cefotaxinie, and much better than ceftazidime. Cefepime 
is as active against I? aeruginosa as ceftazidime, while 
cefepime and cefpirome are more active than ceftazidime 
against inducible Entevobacteriaceae [32]. Reasons for this 
include the zwitterion structure of the molecules, 
leading to very rapid membrane penetration and 
attainment of high concentrations in the periplasmic 
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IM191 IM195 IM198 CAZ91 CAZ95 CAZ98 PIP91 PIP95 PIP98 PTZ9I PTZ95 PTZ98 AMK91 AMK95 AMK98 CP91 CP95 CP98 
Figure 1 Resistance towards different antibiotics for 1991 and 1995 in a sample of Belgian intensive care units from 
regional and university hospital-the NPRS studies [29-311. SEMC=Inducible Enterobacteriaceae: Servatia, Enterobacter, 
Movganella and Citrohacter spp. 
E. coli + Kleb=non-inducible Enterobacteriaceae 
IMI=imipeneni; CAZ=ceftazidime; PIP=piperacillin; PTZ=piperacillin+ tazobactarn; AMK=amikacin; CP=ciprofloxacin. 
Permission to cite from the NPRS data was obtained from MSD Belgium. The NPRS data are protected by copyright and 
can only be used, in part or as a whole, after obtaining written permission from Merck Sharpe & Dohnie BV, 
Waterloosesteenweg 11 35, 1180 Brussels, Belgium. 
532 Clinical Microbio logy and Infection, Volume 5 Supplement 1 
space; high affinity for penicillin binding proteins, 
good stability against beta-lactamases and low selection 
pressure for resistance. Cefhirome seems more active 
against Gram-positives and cefepime more active against 
the inducible Gram-negatives. Fourth generation ceph- 
alosporins could be an important arm in combating the 
emerging 'epidemic' of ICU-related infections with 
inducible Gram-negatives, especially Enterobacter sp. 
THE ANTWERP EXPERIENCE WITH CEFEPIME IN 
COMBATING INCREASING ANTIBIOTIC RESISTANCE 
The University Hospital of Antwerp is a 600-bed 
hospital, serving as a secondary line and referral 
hospital. Its potential catchment area includes a 
population of 1.2 d i o n  inhabitants. It offers extensive 
cardiovascular surgery services and organ transplant 
facilities. The ICU consists of 30 fully equipped beds, 
divided over four adjacent units, each with a specific 
patient profile. It serves about 2,000 patients per year, 
with a mean of 4.7 days per admittance. Sixty five per 
cent of patients are ventilated for more than one day. 
For several years now, a hospital-wide survey has 
been performed of all microorganisms isolated accord- 
ing to body site and sensitivity pattern. These data were 
collected on a departmental basis. Therefore, different 
guidelines could be created for different clinical units. 
While the antibiotics committee decided on a hospital- 
wide antibiotic policy, after discussion it was decided to 
create a specific subset of prescription rules for the 
neonatology, hematology and ICU departments, based 
on the specific needs of these distinct patient classes. 
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Figure 2 Incidence of E. aerogenes and E. cloacae on the University Hospital Antwerp Department of Intensive Care. An 
important increase in incidence in the second half of 1996 led to the introduction of cefepime in the blind 'start' therapy of 
nosocomial infections from January 1997 onwards. The dramatic fall in Enterobacter isolation is apparent from the graph. 
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This ongoing surveillance of the microbiological 
flora and sensitivity patterns recently led to important 
guideline changes in both the hematology and ICU 
department. 
As reported by Mebis et al. 1331, from May 1995 
onwards, ceftazidime monotherapy was replaced by 
cefepime plus amikacin for empirical therapy of pre- 
sumed nosocomial infections in hematology patients. 
Nosocomial infections in the ICU patients were treated 
with a combination of aztreonam plus cloxacillin plus 
amikacin until January 1997, when this was switched to 
cefepime plus amikacin (or cefepime plus ciprofloxacin 
in a case of failing kidney function). These changes 
were made, when an important increase in incidence 
of inducible Enterobacteriaceae was noted in both depart- 
Table 1 Percentage resistance of inducible Enterobacteriaceae, 
isolated from all body sites on the ICU from 1994 onwards. 
After cefepirne introduction in January 1997, there was a 
fall in CTZ resistance, while ciprofloxacin resistance kept 
increasing. Cefepime resistance remained stable over this 
period 
Inducible 
Entrrobacteriaceac 
all body sites 1994 1995 1996 1997 
CTZ 
AZT 
P w  
PTZ 
CIP 
AMK 
CEFE 
IMI 
17 39 
11 34 
10 46 
13 33 
1 16 
3 11 
11 
1 1 
55 
51 
60 
50 
35 
10 
8 
1 
44 
43 
54 
42 
42 
10 
12 
9 
C T Z  =ceftazidime; AZT=aztreonatn; PIP=piperacillin; 
I’TZ =yiperacilliii-tazobactani; CIP=ciprofloxacin; 
AMK=arnikaciri; CEFE= ccfepime; IMI =imipeneni. 
Table 2 Percentage resistance of inducible Enterobacteriaceae, 
isolated from blood cultures on the ICU from 1994 
onwards. Again, there was a fall in ceftazidime and 
yuinolone resistance. Cefepime resistance remained stable 
over this period 
Inducible 
En terohacteriact-ae 
blood cultures 1994 1995 1996 1997 
C T Z  
AZT 
PIP 
PTZ 
CII’ 
AMK 
CEFE 
1MI 
14 25 
14 25 
21 SO 
21 38 
0 13 
7 0 
0 
0 0 
69 
s 4  
69 
54 
46 
8 
8 
0 
64 
55 
64 
55 
36 
9 
9 
10 
C T Z  =ceftazidime; AZT=aztreonatii; PIP= piperacillin; 
I’TZ =piperacilliii-tazobactam; CIP= ciprofloxacin; 
AMK=aniikacin; CEFE=cefepime; IMI =imipeneni. 
ments, together with increasing resistance towards 
ceftazidime and aztreonam. 
In the Hematology department, this change in 
prescription habits was followed by a sustained decrease 
in resistance in inducible Enterobacteriaceae towards 
ceftazidime and ciprofloxacin; the already low resistance 
in I? aeruginosa remained unchanged [33]. 
In the intensive care unit, the introduction of 
cefepime led to a remarkable drop in the number of 
E. cloacae and, to a lesser extent, E. aerogenes isolates 
Table 3 Percentage resistance of inducible Enterobacteriaceae, 
isolated from respiratory samples on the ICU in 1996 and 
1997 
Inducible 
Enterobacteriaceae 
respiratory samples 1996 1997 
C T Z  51 36 
AZT 51 36 
PIP 54 5 0 
PTZ 45 44 
CIP 30 39 
AMK 7 10 
CEFE 5 11 
IM 1 0 6 
CTZ=ceftazidime; AZT=aztreonam; PIP=pipcraciUiii; 
PTZ = piperacillin-tazobactam; CIP = ciprofloxacin; 
AMK =arnikacin; CEFE=crfepime; IMI =imipenern. 
(Figure 2). Furthermore, as can be seen from Tables 
1-3, resistance towards ceftazidinie fell for isolates of all 
body sites and ceftazidime resistance in inducible 
Enterobacteviareae fell in blood and respiratory isolates. 
CONCLUSIONS 
It is necessary to continually evaluate the local micro- 
bial flora and its resistance profile in order to formulate 
specific sets of prescription guidelines and to change 
these when necessary. Individual antibiotic therapy 
must always be adapted to the patient and his disease. 
Inducible Enterobacteriaceae, certainly Enterobactev sp., are 
at this moment an important problem on the ICU in 
several countries. Fourth generation cephalosporins 
possess some important intrinsic molecular advantages 
which may make them the first choice in settings where 
empirical therapy is needed. However, continuing 
evaluation of efficacy is needed, as for other anti- 
microbial agents. Preliminary data from our hospital’s 
Heinatology and 1CU departments show that a switch 
from ceftazidime or aztreonam to cefepime had 
beneficial effects on infection with inducible Entevo- 
bacteriaceae and on resistance profiles. 
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